A comparison of PK/PD dose response characteristics of glargine in type 2 diabetics.
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Vanderbilt University
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2015 Actual Patient number changed from 14 to 20,Treatment arms changed from 5 to 1,time frame for Primay end point (Glucose Infusion Rate )is changed from 1year to 24 hours as reported by ClinicalTrials.gov record.
- 14 Jun 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.